Samriddhiprogressive Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 13-12-2024
- Paid Up Capital ₹ 0.50 M
as on 13-12-2024
- Company Age 9 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 M
as on 13-12-2024
- Revenue -13.12%
(FY 2019)
- Profit -25.22%
(FY 2019)
- Ebitda -224.94%
(FY 2019)
- Net Worth 11.80%
(FY 2019)
- Total Assets 5.15%
(FY 2019)
About Samriddhiprogressive Pharma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹4.00 M.
Sunil Srivastava, Tapan Mukherjee, and Rachna Srivastava serve as directors at the Company.
- CIN/LLPIN
U74120UP2015PTC071852
- Company No.
071852
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jul 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Samriddhiprogressive Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Srivastava  | Director | 07-Jun-2024 | Current |
| Tapan Mukherjee | Director | 23-Apr-2019 | Current |
| Rachna Srivastava | Director | 06-Jul-2015 | Current |
Financial Performance of Samriddhiprogressive Pharma.
Samriddhiprogressive Pharma Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 13.12% decrease. The company also saw a substantial fall in profitability, with a 25.22% decrease in profit. The company's net worth Soared by an impressive increase of 11.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Samriddhiprogressive Pharma?
In 2018, Samriddhiprogressive Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Suyash Builders And Developers Private LimitedActive 20 years 4 monthsSunil Srivastava is a mutual person
- Sukh Samriddhi Alfa Estate Private LimitedActive 4 years 19 days
Sunil Srivastava is a mutual person
- Samriddhi Sukh Enterprises Private LimitedActive 14 years 5 days
Sunil Srivastava is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 11 Oct 2018 | ₹4.00 M | Open |
How Many Employees Work at Samriddhiprogressive Pharma?
Unlock and access historical data on people associated with Samriddhiprogressive Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Samriddhiprogressive Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Samriddhiprogressive Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
